Each lupus patient’s disease is unique, but specific biomarkers like Type-1 Interferon (IFN-1) are known to play a role in SLE disease activity.

By measuring a patient’s biomarkers, it may be possible to predict disease progression, response to standard therapy, and may help to identify patients that may benefit from targeted therapy.